Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands…
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from…
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
